Our story
Born in Switzerland, for global impact.
XEMPERIA SA was founded in 2023 as a spin-off from the University of Fribourg, Switzerland. Based on more than 25 years of research in cancer biology, translational medicine and biomarker discovery, Prof. Curzio Rüegg and his team developed solutions based on the newest scientific knowledges and technologies. Built on over 25 years of pioneering translational cancer research and biomarker discovery expertise.
From scientific discoveries to a new approach to cancer detection.
The starting point was a simple question: Could the body react to breast cancer before the tumor manifests itself?
The scientific discoveries. Our research showed that breast cancer induces characteristic molecular changes in the circulating immune cells in breast cancer patients.
A simple and efficient blood test to detect early cancer. This discovery became the foundation for our blood-based a PCR test detecting woman with early breast cancer
Nanotechonologies to detect circulating cancer biomarkers. Our technologies allow rapid, sensitive, and cost-effective detection of nucleic acids.
Our Team and Advisors
Science, medicine and entrepreneurship working together.
XEMPERIA brings together complementary expertise in cancer biology, molecular diagnostics, nanotechnology, data science and business.
Prof. Curzio Rüegg
Founder, CEO/CSO
Cancer biology · Translational research · Biomarkers
Dr. Sarah Cattin
Founder, CTO
Cancer Biology · Technology · Molecular tests
Dr. Ivana Domljanovic
Chief Nanotechnology Officer (CNO)
DNA nanotechnology · Molecular diagnostics
Sofia Bernasconi
Communication · Public engagement · Awareness
Dr. Med, PD Khali Zaman
Advisor
Clinical oncology
Dr. Sahar Hosseinian
Advisor
Biomarkers · Bioinformatics · Statistics
Matthieu Piller
Advisor
Business strategy · Management
Gabrielle Gache
Advisor
Marketing
The SAB
XEMPERIA is supported by a Scientific Advisors Board (SAB) consisting of leaders in cancer biology, cancer biomarkers, translational and clinical oncology
Prof. Klaus Pantel
Director of the Tumor Biology Institute, Universitäts Klinikum Eppendorf, Hamburg, Germany. Pioneer of the liquid biopsy field.
Prof. Suzette Delaloge
MD, Clinical oncologist, Director of the Interception medico-scientific program, Institut Gustave Roussy, (IGFR), Paris, France.
Prof. Christine Desmedt
PhD, Translational Breast Cancer, Research. Katholieke Universiteit Leuven (KLU), Leuven, Belgium.
Dr. Mauro Delorenzi
PhD, Biologist Translational Bioinformatics and Statistics. Emeritus head of Bioinformatics Core Facility (BCF) UNIL-SIB, Lausanne, Switzerland.
Prof. Olivia Pagani
MD, Clinical oncologist. Member of the International Breast Cancer Study Group (IBCSG). Emeritus head breast cancer clinic and research, IOSI, Bellinzona, Switzerland.
Prof. Christine Desmedt
PhD, Translational Breast Cancer, Research. Katholieke Universiteit Leuven (KLU), Leuven, Belgium
Interested in knowing more?
- © 2025 Xemperia. All rights reserved | Imprint | Design: ZebraZbinden | Development: FRESCHI IT